Live news related to TME PHARMA stock (NL0015000YE1): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on TME PHARMA mainly cover analyst notes, M&A activity et guidance and outlook. The stock trades at €0,10 on Euronext Paris, down 0,39% at the last update. This page lists the articles published on TME PHARMA stock to track the share price, company announcements and any item likely to influence market perception.
The only firm commitments are limited to six months of exclusivity and a non-refundable fee of €150,000. A definitive agreement would only take effect…
TME Pharma published its first-half 2026 financial statements on 30 October 2026. The net loss amounts to €0.51 million, compared with €2.1 million a …
The outlined financial terms remain non-binding and would only apply upon signature of a definitive agreement. This agreement is presented by both com…
In a press release published on October 26, 2026, the biotechnology company listed on Euronext Growth Paris indicated that the postponement of its mat…
In a letter to its shareholders, the chief executive of the Berlin-based biotech company, listed on Euronext Growth Paris, outlines the progress of it…
The oncology-focused biotech is experiencing a spectacular intraday jump, following a press release published on Monday, August 24, on the progress of…
The biotechnology company provided an update on its activities on August 24, 2026, clarifying that it is entering the final evaluation phase of advanc…
TME Pharma released its annual 2025 results on Thursday, showing an improvement in its net loss, which fell to €3.3 million from €5.7 million the prev…
TME Pharma announced on Thursday the publication in Nature Communications of the results of its GLORIA trial, highlighting a significantly higher over…
TME Pharma announces in a press release that certain lenders have agreed to extend the duration of their loans by an additional 12 months, ensuring it…